• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Fragile X Syndrome Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome.
  • The report assesses Fragile X Syndrome pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Fragile X Syndrome pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Fragile X Syndrome ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

Neuren Pharmaceuticals, Addex Pharmaceuticals, Seaside Therapeutics, Ecopia BioSciences, NexGenix Pharmaceuticals, Neuropharm, Merck & Co, Afraxis, Sage Therapeutics, Kareus Therapeutics, Zynerba Pharmaceuticals, Selvita, Hua Medicine, Confluence Pharmaceuticals, Fulcrum Therapeutics, Vencerx Therapeutics, Purdue Pharma, Cortex Pharmaceuticals, XenoPort, Roche, Alcobra, Neurotrope BioScience

Key Drugs:

Trofinetide, Diazepinomicin, Fenobam, STX 107, KU 046, ZYN 002, AMO 01, Acamprosate, Ganaxolone, Memantine, Gaboxadol, Basimglurant, Arbaclofen, Metadoxine extended-release, Bryostatin, Mavoglurant, ANAVEX 2-73

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel